Leukemia-associated antigen-specific T cell

"Leukemia-associated antigen-specific T cells" does not denote a single, well-defined molecular therapeutic target such as a receptor, enzyme, transporter, or transcription factor, but instead refers to **T lymphocytes whose T-cell receptors (TCRs) are specific for leukemia-associated antigens (LAAs) or tumor-associated antigens (TAAs) expressed by leukemic cells**.[2][4][5] These are functional immune effector cells used in adoptive T-cell immunotherapy, particularly in myeloid leukemias like acute myeloid leukemia, where donor- or patient-derived T cells are expanded ex vivo against one or more leukemia-associated antigens such as WT1, PRAME, proteinase 3, neutrophil elastase, MAGE-A3 and others, and then infused to mediate graft‑versus‑leukemia or antitumor effects.[2][3][4][5] Because this phrase describes a T-cell product or response rather than a discrete molecular entity, it is not considered a canonical drug target; the true molecular targets in this context are the individual leukemia-associated antigens (e.g., WT1, PRAME, hTERT, survivin, MAGE family antigens) that are recognized by these T cells.[2][3][4]

Other names

Leukemia-associated antigen-specific cytotoxic T lymphocyteLeukemia-associated antigen-specific CTLLeukemia-associated antigen-specific T lymphocyteLeukemia antigen-specific T cellLeukemia tumor-associated antigen-specific T cell